Skip to main content

Table 1 Baseline demographics and clinical characteristics among participants of the BETAEVAL study (N = 143)

From: Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study

Characteristic

 

Age, years

 Mean (SD)

41.2 (11.5)

 Median (range)

40 (21–79)

Gender, n (%)

 Women

99 (69.2)

 Men

44 (30.8)

BMI, kg/m2

 Mean (SD)

25.8 (5.2)

 Median (range)

24.5 (17.6–47.8)

Diagnosis, n (%)

 

 RRMS

136 (95.1)

 CIS

7 (4.9)

Time between first symptoms and initial diagnosis, months; (N = 87)

 Mean (SD)

15.2 (29.4)

 Median (range)

1.32 (0–137.3)

Duration of disease, months; (N = 105)

 Mean (SD)

57.5 (73.0)

 Median (range)

29.9 (0.0–372.6)

EDSS, median (range); (N = 124)

2.0 (0–6.5)

Previous treatment, n (%)

 Betaferon®

106 (74.1)

 Other treatment

6 (4.2)

 No previous treatment

31 (21.7)

Previous usage of auto-injector for Betaferon® treatment among patients who received Betaferon® previously (N = 106), n (%)

 Any

84 (79.3)

  BETACOMFORT®

51 (60.7)

  BETAJECT Comfort®

20 (23.8)

  BETAJECT lite®

3 (3.6)

  Other

10 (11.9)

Participation in BETAPLUS® nurse support programme, n (%)

87 (60.8)

Employment status, n (%)

 Employed

107 (74.8)

 Retired

13 (9.1)

 Keeping house

7 (4.9)

 Student

3 (2.1)

 Seeking work

3 (2.1)

 Self-employed

2 (1.4)

 Other

3 (2.1)

  1. Numbers (%) may not add up to total numbers (100%) due to missing values
  2. SD standard deviation, BMI body mass index, RRMS relapsing remitting multiple sclerosis, CIS clinically isolated syndrome, EDSS expanded disability status scale